JP7617076B2 - Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 - Google Patents

Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 Download PDF

Info

Publication number
JP7617076B2
JP7617076B2 JP2022504181A JP2022504181A JP7617076B2 JP 7617076 B2 JP7617076 B2 JP 7617076B2 JP 2022504181 A JP2022504181 A JP 2022504181A JP 2022504181 A JP2022504181 A JP 2022504181A JP 7617076 B2 JP7617076 B2 JP 7617076B2
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
carcinoma
pharma
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541825A (ja
JPWO2021012049A5 (https=
JP2022541825A5 (https=
Inventor
エヌ． クレイン、シェルドン
リン チュオン、ヴォイ
アブドリ、アッバス
トルション、ジャン－フランソワ
ブラック、キャメロン
ドリッチ、ステファーヌ
フェーダー、リー
ラノワ、ステファニー
ジョーンズ、ポール
セント－オンジェ、ミゲル
ピカール、オードリー
エム． ラックベイ、サイラス
Original Assignee
リペア セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2019/051539 external-priority patent/WO2020087170A1/en
Application filed by リペア セラピューティクス インコーポレイテッド filed Critical リペア セラピューティクス インコーポレイテッド
Publication of JP2022541825A publication Critical patent/JP2022541825A/ja
Publication of JPWO2021012049A5 publication Critical patent/JPWO2021012049A5/ja
Publication of JP2022541825A5 publication Critical patent/JP2022541825A5/ja
Priority to JP2025001996A priority Critical patent/JP7758895B2/ja
Application granted granted Critical
Publication of JP7617076B2 publication Critical patent/JP7617076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022504181A 2019-07-22 2020-07-22 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 Active JP7617076B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001996A JP7758895B2 (ja) 2019-07-22 2025-01-06 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962877177P 2019-07-22 2019-07-22
US62/877,177 2019-07-22
CAPCT/CA2019/051539 2019-10-30
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PCT/CA2020/051014 WO2021012049A1 (en) 2019-07-22 2020-07-22 Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001996A Division JP7758895B2 (ja) 2019-07-22 2025-01-06 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Publications (4)

Publication Number Publication Date
JP2022541825A JP2022541825A (ja) 2022-09-27
JPWO2021012049A5 JPWO2021012049A5 (https=) 2023-07-31
JP2022541825A5 JP2022541825A5 (https=) 2023-07-31
JP7617076B2 true JP7617076B2 (ja) 2025-01-17

Family

ID=74192632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504181A Active JP7617076B2 (ja) 2019-07-22 2020-07-22 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
JP2025001996A Active JP7758895B2 (ja) 2019-07-22 2025-01-06 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001996A Active JP7758895B2 (ja) 2019-07-22 2025-01-06 Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Country Status (16)

Country Link
US (1) US20220185809A1 (https=)
EP (1) EP4003993A4 (https=)
JP (2) JP7617076B2 (https=)
KR (1) KR20220035925A (https=)
CN (1) CN114174292B (https=)
AU (1) AU2020317381A1 (https=)
BR (1) BR112022000431A2 (https=)
CA (1) CA3148278A1 (https=)
CO (1) CO2022001853A2 (https=)
CR (1) CR20220068A (https=)
EC (1) ECSP22012347A (https=)
IL (1) IL289763A (https=)
MX (1) MX2022000854A (https=)
PH (1) PH12022550156A1 (https=)
UA (1) UA129807C2 (https=)
WO (1) WO2021012049A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025061048A (ja) * 2019-07-22 2025-04-10 リペア セラピューティクス インコーポレイテッド Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210281A (es) 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
CA3164203A1 (en) * 2019-12-11 2021-06-17 Repare Therapeutics Inc. Use of atr inhibitors in combination with parp inhibitors
BR112023022481A2 (pt) * 2021-04-28 2024-02-15 Repare Therapeutics Inc Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica
MX2023014302A (es) * 2021-06-04 2024-02-28 Repare Therapeutics Inc Formas cristalinas, composiciones que contienen las mismas y métodos para su uso.
KR20240041354A (ko) * 2021-07-27 2024-03-29 릿츠뜨 메디시네스 엘티디 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도
CN113856764B (zh) * 2021-10-29 2022-11-01 华中科技大学 一种过渡金属催化剂及其制备方法和应用
CN116099390B (zh) * 2022-11-14 2024-07-23 石河子大学 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用
WO2024211696A1 (en) * 2023-04-07 2024-10-10 Biogen Ma Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025181153A1 (en) * 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
JP2017523987A (ja) 2014-08-04 2017-08-24 バイエル・ファルマ・アクティエンゲゼルシャフト ２−（モルホリン−４−イル）−１，７−ナフチリジン
JP2019508384A (ja) 2016-01-14 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795573B1 (en) * 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
JP5889875B2 (ja) * 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
ES2951688T3 (es) * 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
RS61688B1 (sr) * 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
JP2017523987A (ja) 2014-08-04 2017-08-24 バイエル・ファルマ・アクティエンゲゼルシャフト ２−（モルホリン−４−イル）−１，７−ナフチリジン
JP2019508384A (ja) 2016-01-14 2019-03-28 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2015年，6(1)，42-46
Neres, Joao et al.，Non-nucleoside inhibitors of BasE, an adenylating enzyme in the siderophore biosynthetic pathway of，Journal of Medicinal Chemistry，2013年，56(6)，2385-2405

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025061048A (ja) * 2019-07-22 2025-04-10 リペア セラピューティクス インコーポレイテッド Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
JP7758895B2 (ja) 2019-07-22 2025-10-22 リペア セラピューティクス インコーポレイテッド Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体

Also Published As

Publication number Publication date
JP2022541825A (ja) 2022-09-27
JP2025061048A (ja) 2025-04-10
MX2022000854A (es) 2022-02-10
ECSP22012347A (es) 2022-03-31
CA3148278A1 (en) 2021-01-28
CR20220068A (es) 2022-06-30
KR20220035925A (ko) 2022-03-22
AU2020317381A1 (en) 2022-02-10
BR112022000431A2 (pt) 2022-03-03
UA129807C2 (uk) 2025-08-06
WO2021012049A8 (en) 2021-04-15
EP4003993A4 (en) 2023-01-18
EP4003993A1 (en) 2022-06-01
CN114174292B (zh) 2024-06-18
PH12022550156A1 (en) 2023-05-08
WO2021012049A1 (en) 2021-01-28
CO2022001853A2 (es) 2022-03-29
US20220185809A1 (en) 2022-06-16
IL289763A (en) 2022-03-01
CN114174292A (zh) 2022-03-11
JP7758895B2 (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
JP7758895B2 (ja) Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
JP2024105340A (ja) 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
EP4126879B1 (en) N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer
US12435090B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
EP4125907A1 (en) Methods of using myt1 inhibitors
RU2806857C2 (ru) Соединения, фармацевтические композиции, способы приготовления соединений и их применение в качестве ингибиторов киназы atr
HK40070621A (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
EA047254B1 (ru) Производные замещенного 2-морфолинопиридина в качестве ингибиторов atr-киназы
HK40070621B (zh) 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物
EA052456B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения
EA050141B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения
BR122024006404A2 (pt) Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617076

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150